Popular Articles

New Non Executive Joins Board Of Somerset Mental Health Trust
Somerset Partnership NHS Foundation Trust has announced the appointment of a new Non Executive Director to its Board.

NHLBI Funds Global Centers On Chronic Diseases And Collaborates With UnitedHealth Group
NHLBI Funds Research and Training Centers Aimed at Prevention and Treatment of Chronic Diseases in Developing Countries and Collaborates with UnitedHealth Group"s Chronic Disease Initiative
News of the day
Bloggers Scrutinize Fox News' O'Reilly's Past Comments On Murdered Abortion Provider Tiller
Some liberal journalists and bloggers are criticizing Fox News host Bill O"Reilly for the language he has used when discussing abortion provider George Tiller, with some suggesting that his harsh rhetoric incites violence, the New York Times reports. Tiller, who was one of a small number of U.S. doctors who performed abortions later in pregnancy, was shot and killed on Sunday while serving as an usher in his local church. On Monday, O"Reilly said that "clear-thinking Americans should condemn" the murder but also defended his past remarks about Tiller. O"Reilly said that "every single thing we said about Tiller was true, and my analysis was based on those facts."Salon within nine hours of Tiller"s death had posted video clips of 29 on-air references that O"Reilly had made about Tiller on past programs. O"Reilly has said that Tiller and other abortion providers conduct the "business of destruction" and that he "wouldn"t want to be these people if there is a Judgment Day." Media Matters for America on its site published a 2006 clip in which O"Reilly said, "If I could get my hands on Tiller," adding, "Well, you know. Can"t be vigilantes. Can"t do that. It"s just a figure of speech."According to the Times, O"Reilly often draws particular attention because his cable news show has held a No. 1 rating for the past seven years. Burt Neuborne, a New York University law professor and a former legal director for the American Civil Liberties Union, said that a commentator"s language, regardless of its severity, usually cannot be treated as an incitement of violence unless it includes direct instructions to individuals. He added, "It"s important not to allow that to happen. It would have a dramatic effect on the ability to speak vigorously" (Stelter, New York Times, 6/2).
Oncology

Advaxis Receives FDA Response To Orphan Drug Filing

Advaxis, Inc. (OTCBB:ADXS) received the FDA letter late on June 1 denying the company"s request for Orphan Drug Designation (ODD) for the use of ADXS11-001 in invasive cervix cancer. The FDA stated their market definition for invasive cervical cancer prevalence (including all those who had been cured) is over the 200,000 person cutoff. Further, the applicability of ADXS11-01 for a precursor condition, cervical intraepithelial neoplasia (CIN) was considered by the ODD as an early manifestation of the disease. No prevalence estimate for CIN was provided in our original application. There was no issue raised about efficacy. Advaxis Chairman and CEO Thomas Moore commented, "When we announced this ODD filing, we said it was historically a 50% probability of getting approved. With an annual incidence of only 10,000 patients in the US diagnosed with invasive cervical cancer and a very poor prognosis if standard therapies fail, which they do for about half these patients, this appeared to be just what Orphan Drug was designed to encourage. The FDA Office of Orphan Products Development was very cooperative with us but we are naturally disappointed. "We have pending study activity in cervical cancer in collaboration with NCI and plan to conduct at least one additional off-shore study. Our Phase I results showed great promise. We will likely seek another regulatory route for this indication, Fast Track designation, for which we can apply in the near term. If approved, Fast Track provides similar advantages in regulatory acceleration, but provides no market exclusivity or the possibility of grant support from FDA." Advaxis, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):